 Grifols MCE:GRF, MCE:GRF.P NASDAQ:GRFS, a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL 900-IU vial for HyperRAB rabies immune globulin human, a treatment for rabies postexposure prophylaxis. 